These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

582 related articles for article (PubMed ID: 16942028)

  • 21. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
    Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
    Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, characterization, antiproliferative and anti-metastatic properties of two ruthenium-DMSO complexes containing 2,2'-biimidazole.
    Tan C; Hu S; Liu J; Ji L
    Eur J Med Chem; 2011 May; 46(5):1555-63. PubMed ID: 21354673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
    Auzias M; Therrien B; Süss-Fink G; Stepnicka P; Ang WH; Dyson PJ
    Inorg Chem; 2008 Jan; 47(2):578-83. PubMed ID: 18085776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
    Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
    Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents.
    Gras M; Therrien B; Süss-Fink G; Zava O; Dyson PJ
    Dalton Trans; 2010 Nov; 39(42):10305-13. PubMed ID: 20890536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents.
    Cini R; Tamasi G; Defazio S; Corsini M; Zanello P; Messori L; Marcon G; Piccioli F; Orioli P
    Inorg Chem; 2003 Dec; 42(24):8038-52. PubMed ID: 14632524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, characterization and assessment of the cytotoxic properties of cis and trans-[Pd(L)(2)Cl(2)] complexes involving 6-benzylamino-9-isopropylpurine derivatives.
    Trávnícek Z; Szucová L; Popa I
    J Inorg Biochem; 2007 Mar; 101(3):477-92. PubMed ID: 17208304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties.
    Pelletier F; Comte V; Massard A; Wenzel M; Toulot S; Richard P; Picquet M; Le Gendre P; Zava O; Edafe F; Casini A; Dyson PJ
    J Med Chem; 2010 Oct; 53(19):6923-33. PubMed ID: 20822096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex.
    Hotze AC; van der Geer EP; Caspers SE; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
    Inorg Chem; 2004 Aug; 43(16):4935-43. PubMed ID: 15285670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective cytotoxic Ru(II) arene Cp* complex salts [R-PhRuCp*](+)X(-) for X = BF4(-), PF6(-), and BPh4(-).
    Loughrey BT; Healy PC; Parsons PG; Williams ML
    Inorg Chem; 2008 Oct; 47(19):8589-91. PubMed ID: 18783214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
    Yan YK; Melchart M; Habtemariam A; Sadler PJ
    Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruthenium(II) arene anticancer complexes with redox-active diamine ligands.
    Bugarcic T; Habtemariam A; Deeth RJ; Fabbiani FP; Parsons S; Sadler PJ
    Inorg Chem; 2009 Oct; 48(19):9444-53. PubMed ID: 19780621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on the reactivity of organometallic Ru-, Rh- and Os-pta complexes with DNA model compounds.
    Dorcier A; Hartinger CG; Scopelliti R; Fish RH; Keppler BK; Dyson PJ
    J Inorg Biochem; 2008; 102(5-6):1066-76. PubMed ID: 18086499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arene ruthenium complexes as anticancer agents.
    Süss-Fink G
    Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells.
    Biersack B; Zoldakova M; Effenberger K; Schobert R
    Eur J Med Chem; 2010 May; 45(5):1972-5. PubMed ID: 20149940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
    Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
    J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of high in vitro and in vivo antitumor activities of organometallic ruthenium(ii)-arene complexes with 5,7-dihalogenated-2-methyl-8-quinolinol.
    Meng T; Qin QP; Chen ZL; Zou HH; Wang K; Liang FP
    Dalton Trans; 2019 Apr; 48(16):5352-5360. PubMed ID: 30942794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.